Marcelo José Oliveira’s biography, net worth, fact, career, awards and life story

Intro Brazilian footballer
Is Athlete 
Football player 
Association football player 
From Brazil 
Type Sports 
Gender male
Birth 5 September 1981, Santa Rita do Sapucaí
Age: 38 years

Marcelo José Oliveira (born 5 September 1981 in Santa Rita do Sapucaí), commonly known as Marcelo Oliveira, is a Brazilian football defender who plays for Moreirense in the Portuguese Primeira Liga.

Club career

Corinthians / Grêmio

Oliveira started his career at Brazil, where he played for Corinthians and Grêmio.

Atromitos

In 2006, he moved to the Greek club Atromitos and he stayed at the club for five seasons, appearing in 117 matches and scoring 8 goals.

APOEL

On 9 June 2011, he signed a two-years contract with the Cypriot club APOEL. In his first season at the club, he won the Cypriot Super Cup and appeared in eight 2011–12 UEFA Champions League matches for APOEL, in the club’s surprising run to the quarter-finals of the competition. He became a champion for the first time in his career after winning the 2012–13 Cypriot First Division with APOEL. During the 2013–14 season, he appeared in five 2013–14 UEFA Europa League group stage matches for APOEL and won all the titles in Cyprus, the Cypriot League, the Cypriot Cup and the Cypriot Super Cup.

Moreirense

On 14 July 2014, he signed a one-year contract with the Portuguese side Moreirense.

Honours

APOEL
  • Cypriot First Division (2) : 2012–13, 2013–14
  • Cypriot Cup (1) : 2013–14
  • Cypriot Super Cup (2) : 2011, 2013
You May Also Like

Patrick Soon-Shiong’s net worth, biography, fact, career, awards and life story

Patrick Soon-Shiong net worth: Patrick Soon-Shiong is a South African-born surgeon and drug developer who has a net worth of $15.5 billion dollars. Patrick Soon-Shiong is currently the richest person in Los Angeles thanks to an extremely lucrative career as a biotech entrepreneur. In 2010, Patrick purchased Magic Johnson’s 4.5% ownership stake in the Los Angeles Lakers. He is the largest Lakers owner outside of the Buss family. With the transaction, Soon-Shiong also acquired four courtside Lakers seats. Soon-Shiong was born to Chinese immigrants in South Africa on July 29, 1952. His parents fled China during World War II and settled in Port Elizabeth, South Africa. After graduating from high school at the age of 16, Patrick earned his medical degree from the University of the Witwatersrand in Johannesburg at the age of 23. He then earned a Master of Science from the University of British Columbia before moving to Los Angeles for surgical training. Soon-Shiong, who now holds over 50 patents, was a member of the UCLA Medical School faculty from 1983 to 1991. From Humble Surgeon to Multi-Billionaire Soon-Shiong left UCLA in 1991 and founded a biotechnology company called Abraxis BioScience. Under Patrick’s leadership, the company eventually developed a revolutionary drug used in the treatment of breast, lung and pancreatic cancers. The drug, Abraxane, was approved by the FDA in 2005 and the European equivalent in 2008 for the treatment of breast cancer when chemotherapy was not working. By 2009, Abraxane generated $315 million in revenue per year. In 2010 Abraxis BioScience, which was still solely owned by Soon-Shiong, was acquired by American biotech company Celgene for $3 billion in cash and stock. Turns out, this acquisition wasn’t even his biggest success in the business world! In 1997, Patrick founded a company called American Pharmaceutical Partners (APP) which manufactured generic intravenous medicines. By 2008, APP was generating $750 million per year in revenue, of which roughly $300 million was pure profit. In July of 2008, Homberg, Germany-based Fresnius SE agreed to acquire APP for $5.6 billion. At the time of the transaction, Patrick Soon-Shiong owned 80% of APP’s shares. Not one to rest on his laurels, Soon-Shiong founded another company called NantWorks in September 2011. Nantworks’s health division NantHealth aims to provide cloud-based data to the healthcare industry. One of the company’s super computers is now able to analyze and transfer the genetic data from a tumor in under a minute.
Read More